Can we build up a storm against hard to treat cancers? The initial evidence suggests, yes we can!
Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to treat solid tumours with a more selective and focused approach to oncology drug development.
We’ve talked about the so-called ‘drugging the undruggable’ targets in the past, but what if we could circle back and use a different approach in combination with existing selective inhibitors currently in the clinic?
These possibilities – and others – caught my attention and they may pique yours too, so what’s this all about?
To learn more from our oncology analysis and get a heads up on insights and commentary emerging on protein degradation, subscribers can log-in or you can click to gain access to BSB Premium Content.
As we continue to follow the emerging KRAS niche longitudinally, we can easily imagine the kind of roller coaster ride that ensues with new product development in oncology R&D.
Early last year we posted an interview with Mirati’s CEO, Dr Chuck Baum, discussing their selective KRASG12C inhibitor. A year on much has happened in the intervening time – additional competitors and potential collaborators have entered the clinic, a few mechanisms of resistance identified, and numerous combination partners have been suggested. The company have also aired their own phase 1 data and new trials are expected to open during 2020.
This time around we talk to both Dr Baum and the company’s CSO, Dr James Christensen, about their experiences in the front line in terms of translating the preclinical data into clinical trials, their thoughts on important scientific data as well as the competition, and what to watch out for going forward.
This field is going to not only go fast judging by the emerging research published to date, but it’s also going to get way more complicated than many observers realise.
To learn more from our oncology coverage and get a heads up on our latest analysis, commentary, and expert interviews from a company active in the KRAS space, subscribers can log-in or you can click to gain access to BSB Premium Content.
River Rhine, Mainz
Mainz, Germany: We’re back for Day 2 highlights from the 2019 Association for Cancer Immunotherapy (CIMT) annual meeting with a look at some insights emerging from some academic and industry talks, as well as gems emerging from the poster halls.
Much attention is focused on cancer immunotherapy clinical data, yet it’s also important to watch out for new developments.
These can take many different forms such as what are companies doing to meet those challenges with novel therapeutics, as well as understanding more detail about immune mechanisms, including evasion and escape as well as defining phenotypes based on different immune cell populations.
As we head into ASCO, let’s not forget that there’s some important learnings to be had elsewhere in the world before we get there…
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.